Table 3.

Most utilized instrument for the assessment of the acute psychedelic experience in clinical research for the four most contributing countries from Jan 1st, 1990 to May 22nd, 2023.

Switzerland (N = 35)	5D-ASC (91.4%)	VAS/Likert (25.7%)	SOCQ/MEQ43 (17.1%)	MEQ30 (8.5%)	ARCI (5.7)
USA (N = 23)	5D-ASC (43.5%)	HRS (39.1%)	SOCQ/MEQ43 (34.8%)	M-scale (26.1%)	ARCI (21.7%)
UK (N = 9)	VAS/Likert (55.6%)	5D-ASC, (33.3%)	MEQ30 (33.3%)	EDI (22.2%)	NDE, CADSS, EBI, PSI, HRS (11.1%)
Spain (N = 7)	HRS (100%)	ARCI (57.1%)	VAS/Likert (57.1%)	APZ (28.5%)	NA

APZ/OAV: Abnormer Psychischer Zustand; ARCI: Addiction Research Center Inventory; CADSS: Clinician-Administered Dissociative States Scale; EBI: Emotional Breakthrough Inventory; EDI: Ego Dissolution Inventory; HRS: Hallucinogen Rating Scale; MEQ30: Mystical Experience Questionnaire 30 items; M-scale: Hood Mysticism Scale; NDE: Near-Death Experience Questionnaire; SOCQ: States of Consciousness Questionnaire; VAS: Visual analog scales developed for the studies; 5D-ASC: Five-Dimension Altered States of Conscious Questionnaire.